With the enormous response from the previous annual Tumor & Cancer Immunology conference 2016, Conference Series LLC invites all the participants from all over the world to attend 2nd International Conference on Tumor & Cancer Immunology-2017 during July 17-19, 2017 in Chicago, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. The Tumor & Cancer Immunology Conference hosting presentations from editors of prominent refereed journals, renowned and active investigators and decision makers in the field of Immunology.

Date : 17th July 2017 to 18th July 2017

Place : United States, Chicago

Website :http://cancerimmunology.conferenceseries.com/

Contact Person:Jennifer Jones

Description:

With the enormous response from the previous annual Tumor & Cancer Immunology conference 2016, Conference Series LLC invites all the participants from all over the world to attend 2nd International Conference on Tumor & Cancer Immunology-2017” during July 17-19, 2017 in Chicago, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. The Tumor & Cancer Immunology Conference hosting presentations from editors of prominent refereed journals, renowned and active investigators and decision makers in the field of Immunology.

With the enormous response from the previous annual Tumor & Cancer Immunology conference 2016, Conference Series LLC invites all the participants from all over the world to attend 2nd International Conference on Tumor & Cancer Immunology-2017 during July 17-19, 2017 in Chicago, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. The Tumor & Cancer Immunology Conference hosting presentations from editors of prominent refereed journals, renowned and active investigators and decision makers in the field of Immunology. will be held in Chicago,United States on date 2017-07-18

---

Deadline for abstracts/proposals : 20th June 2017

Keynote Speakers :

Check the event website for more details.